A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2001
11/15/2001	WO2001085924A2 MODULATION OF η-SECRETASE ACTIVITY
11/15/2001	WO2001085912A2 Presenilin enhancers
11/15/2001	WO2001085797A1 Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
11/15/2001	WO2001085790A2 Mammalian cytokine receptor subunit proteins, related reagents and methods
11/15/2001	WO2001085781A2 Repair of nerve damage
11/15/2001	WO2001085779A2 Protein complexes and assays for screening anti-cancer agents
11/15/2001	WO2001085762A2 Cancer diagnosis and assays for screening anti-cancer agents
11/15/2001	WO2001085755A1 2-substituted pregna-1, 3, 5 (10) -triene and chola-1, 3, 5 (10)-triene derivatives and their biological activity
11/15/2001	WO2001085734A1 Benzoxazines for use in the treatment of parkinson's disease
11/15/2001	WO2001085727A1 Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists
11/15/2001	WO2001085725A1 Piperazine and piperidine compounds
11/15/2001	WO2001085719A1 Ortho-substituted anthranilic acid amides and their use as medicaments
11/15/2001	WO2001085718A1 Hydantoin derivatives with affinity for somatostatin receptors
11/15/2001	WO2001085714A1 Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by the np y5 receptor
11/15/2001	WO2001085712A1 Method for the preparation of citalopram
11/15/2001	WO2001085701A1 5-ht7 receptor antagonists
11/15/2001	WO2001085698A1 New polycyclic indanylimidazoles with alpha2 adrenergic activity
11/15/2001	WO2001085695A1 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
11/15/2001	WO2001085693A1 N-acyltetrahydroisoquinoline derivatives
11/15/2001	WO2001085686A2 Multicyclic compounds and the use as inhibitors of parp, vegfr2 and mlk3 enzymes
11/15/2001	WO2001085685A1 Heterocyclic inhibitors of glycogen synthase kinase gsk-3
11/15/2001	WO2001085677A1 Amino acid derivatives and their use as medicines
11/15/2001	WO2001085671A2 Anthranyl amides and their use as medicaments
11/15/2001	WO2001085669A1 Novel spiro[2.4]heptane amino carboxy compounds and derivatives thereof
11/15/2001	WO2001085257A2 Opioid antagonist compositions and dosage forms
11/15/2001	WO2001085256A2 Critical illness neuropathy
11/15/2001	WO2001085204A2 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
11/15/2001	WO2001085203A2 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
11/15/2001	WO2001085200A2 Recombinant human cln2 protein and methods of its production and use
11/15/2001	WO2001085194A1 Method and composition for the treatment of angiogenesis
11/15/2001	WO2001085178A1 Nutritional preparation comprising ribose and folic acid and medical use thereof
11/15/2001	WO2001085169A2 R-eliprodil for treating glaucoma
11/15/2001	WO2001085168A1 Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders
11/15/2001	WO2001085165A2 Combination of lipoic acid and c1 donors for the treatment of disorders of the central nervous system
11/15/2001	WO2001085152A2 R-eliprodil for treating glaucoma
11/15/2001	WO2001085150A2 Opioid antagonist containing composition for enchaching the potency or reducing adverse side effects ofopioid agonists
11/15/2001	WO2001085149A2 Felbamate derived compounds
11/15/2001	WO2001085147A2 STABILIZED FORMULATIONS OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL) BENZO[b]THIOPHENE AND SALTS THEREOF
11/15/2001	WO2001085145A2 A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
11/15/2001	WO2001085093A2 Compounds and methods for modulating cerebral amyloid angiopathy
11/15/2001	WO2001060375A8 Use of 7alpha-hydroxy-estradiol, 7alpha-hydroxy-dehydroepiandrosterone and 7alpha-hydroxy-pregnenolone derivatives for treating acute cellular degeneration
11/15/2001	WO2001055172A3 ISOLATED COMPLEX COMPRISING A NNT-1 PROTEIN AND IN ADDITION AT LEAST A CLF-1 PROTEIN AND/OR A sCNTFRα PROTEIN
11/15/2001	WO2001047498A3 Hydrogel-driven layered drug dosage form comprising sertraline
11/15/2001	WO2001042794A3 Method for identifying inhibitors of cytokinesis
11/15/2001	WO2001040185B1 Compounds, compositions, and methods for stimulating neuronal growth and elongation
11/15/2001	WO2001034601A3 Imidazopyridine derivatives as phosphodiesterase vii inhibitors
11/15/2001	WO2001017963A3 Aminoalkoxy carbazoles and their use as 5-ht ligands
11/15/2001	WO2001016136B1 Tricyclic inhibitors of poly(adp-ribose) polymerases
11/15/2001	WO2001012202A3 Use of chemical chelators as reversal agents for drug-induced neuromuscular block
11/15/2001	WO2001002550A3 Cell death related drug targets in yeast and fungi
11/15/2001	WO2000078344A8 Prion protein peptides and uses thereof
11/15/2001	WO2000063379A3 The p2x3 receptor, methods of altering p2x3 receptor activity and uses thereof
11/15/2001	WO2000057865A9 Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation
11/15/2001	WO2000055323A9 Differential expression of organellar gene products
11/15/2001	WO2000050872A9 A system for cell-based screening
11/15/2001	WO2000026370A9 Adenine nucleotide translocator (ant) fusion proteins and uses thereof
11/15/2001	US20010041815 Psychological disorders
11/15/2001	US20010041746 Reduce side effect; analgesics
11/15/2001	US20010041734 Administering nefiracetam
11/15/2001	US20010041732 Use
11/15/2001	US20010041727 Use of pramipexole for the treatment of addictive disorders
11/15/2001	US20010041726 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
11/15/2001	US20010041720 2-Amino-N-((1R)-2-((3R)-3-benzyl-3-(N,N',N' -trimethylhydrazinocarbonyl)piperidin-1-yl)-1-(1H-indol-3-ylmethyl)-2 -oxoethyl)-2-methylpropionamide; increasing rate and extent of growth, milk and wool production
11/15/2001	US20010041719 The use of R (+)-alpha- (2,3-Dimethoxyphenyl) -1- [ 2- (4-fluorophenyl) ethyl] -4-piper idinemethanol for the treatment of sleep disorders
11/15/2001	US20010041717 Chronic, bolus administration of D-threo methylphenidate
11/15/2001	US20010041711 8-(4,4-Bis(p-fluorophenyl)butyl)-1-phenyl-1,3,8-triazospiro(4.5) decan-4-one, for example; treating pain with reduced side effects of opioid analgesics; affinity for opioid receptor-like (ORL1) receptor
11/15/2001	US20010041710 (4R)-1-(4-(4-Fluorophenoxy)benzyl)-2-oxo-imidazolidine-4 -carboxylic acid hydroxyamide, for example; treating various diseases including osteoarthritis, rheumatoid arthritis, cancer, osteoporosis, strokes
11/15/2001	US20010041705 Heterocyclic carboxamides
11/15/2001	US20010041703 Which are growth hormone secretogogues and increase the level of endogenous growth hormone; treating osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair
11/15/2001	US20010041695 Orally administering to a post-menopausal woman a fat soluble vitamin and a fat soluble vitamin absorption increasing effective amount of L-carnitine or salts
11/15/2001	US20010041688 Methods and compositions for the regulation of vasoconstriction
11/15/2001	US20010041181 Relieving pain related to muscle activity or contracture, antispasmodic
11/15/2001	US20010041164 Pharmaceutical preparation for inhalation of an opioid
11/15/2001	DE10022925A1 New indole-carboxamide or azepino-indole derivatives and analogs, are poly-ADP ribose polymerase inhibitors useful e.g. for treating neurodegenerative disease, ischemia, epilepsy, tumors, sepsis or diabetes mellitus
11/15/2001	DE10022856A1 Treating central nervous system disorders e.g. cognitive deficiency or depression, using combination of lipoic acid and C-1 donor e.g. S-adenosyl-methionine
11/15/2001	DE10022510A1 Composition used as folate source in food, feed, nutritional supplements or medicaments, e.g. for prophylaxis of cardiovascular disease includes folic acid and 5-methyl-tetrahydrofolic acid
11/15/2001	CA2691739A1 Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo [b]thiophene and salts thereof
11/15/2001	CA2409759A1 Method and composition for the treatment of angiogenesis
11/15/2001	CA2409758A1 Novel multicyclic compounds and the use thereof
11/15/2001	CA2409729A1 5-ht7 receptor antagonists
11/15/2001	CA2409720A1 A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
11/15/2001	CA2409515A1 Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
11/15/2001	CA2408751A1 2-substituted pregna-1, 3, 5 (10) -triene and chola-1, 3, 5 (10)-triene derivatives and their biological activity
11/15/2001	CA2408666A1 Combination of lipoic acid and c1 donors for the treatment of disorders of the central nervous system
11/15/2001	CA2408665A1 Novel regulator of g protein signalling
11/15/2001	CA2408571A1 Mammalian receptor proteins; related reagents and methods
11/15/2001	CA2408563A1 Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof
11/15/2001	CA2408549A1 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
11/15/2001	CA2408547A1 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
11/15/2001	CA2408486A1 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
11/15/2001	CA2408343A1 N-acyltetrahydroisoquinoline derivatives
11/15/2001	CA2408297A1 Cancer diagnosis and assays for screening anti-cancer agents
11/15/2001	CA2408290A1 New polycyclic indanylimidazoles with alpha2 adrenergic activity
11/15/2001	CA2408213A1 Protein complexes and assays for screening anti-cancer agents
11/15/2001	CA2408166A1 Presenilin enhancers
11/15/2001	CA2408106A1 Opioid antagonist compositions and dosage forms
11/15/2001	CA2408098A1 Opioid antagonist containing composition for enhancing the potency or reducing adverse side effects of opioid agonists
11/15/2001	CA2408010A1 Identification of neural defects associated with the nucleosomal assembly protein 1l2 gene
11/15/2001	CA2408002A1 Enzymatic assays for screening anti-cancer agents
11/15/2001	CA2407864A1 Lipid metabolism enzymes

1 ... 1392 1393 1394 1395 1396 1397 1398 1399 1400 1401 1402 1403 1404 1405 1406 1407 1408 1409 1410 1411 1412 ... 1833